MedTrace Logo

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

NCT04103060 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-11-24

No results posted yet for this study

Summary

This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo

Conditions

  • Vitiligo

Interventions

DRUG

Cerdulatinib 0.37% gel

Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

DRUG

Vehicle gel

Vehicle gel applied topically twice daily for 6 weeks

Sponsors & Collaborators

  • Dermavant Sciences GmbH

    lead INDUSTRY

Principal Investigators

  • Michael McLaughlin · Dermavant Sciences GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2020-11-03
Completion
2020-11-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04103060 on ClinicalTrials.gov